National Guard patrol streets of Washington, DC amid president’s federal takeover - National Guard troops were spotted at ...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, ...

DelveInsight's Tumor-Infiltrating Lymphocyte Therapies Market Size, Target Population, Competitive Landscape & Market ...

A phase 3 study shows Cylembio combined with pembrolizumab improves progression-free survival in advanced melanoma, ...

IO Biotech's phase 3 melanoma trial showed a strong PFS benefit, especially in true 1st-line and PD1-negative patients. Click ...

Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for ...

Apollo.io reports that timing and message clarity are crucial for investor emails, with Thursday morning being the best time to engage.

Cylembio did not meet its primary endpoint of progression-free survival (PFS), but did demonstrate a trend towards ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s dise ...

IN BRIEF) SCHOTT Pharma has introduced the SCHOTT TOPPAC® cartridge, the first ready-to-use polymer cartridge to meet ISO dimensions, offering exceptional ...